Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients

Different mechanisms lead to immune checkpoint inhibitor (ICI) resistance. Identifying clinically useful biomarkers might improve drug selection and patients’ therapy. We analyzed the soluble immune checkpoints sPD1, sPDL1, sLAG3, and sTIM3 using ELISA and their expression on circulating T cells usi...

詳細記述

書誌詳細

主要な著者:	Devayani Machiraju, Melanie Wiecken, Nina Lang, Ingrid Hülsmeyer, Jasmin Roth, Timo E. Schank, Rosa Eurich, Niels Halama, Alexander Enk, Jessica C. Hassel
フォーマット:	Artigo
言語:	Inglês
出版事項:	Taylor & Francis Group 2021-01-01
シリーズ:	OncoImmunology
主題:	melanoma immune checkpoints immunotherapy t lymphocytes
オンライン･アクセス:	http://dx.doi.org/10.1080/2162402X.2021.1926762
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!